Ionis Pharmaceuticals, Inc.
IONS
$55.31
-$0.72-1.28%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -7.41% | 47.53% | 33.83% | 20.41% | 16.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -7.41% | 47.53% | 33.83% | 20.41% | 16.05% |
| Cost of Revenue | 4.88% | 4.04% | 1.23% | -4.05% | -3.63% |
| Gross Profit | -196.26% | 168.00% | 109.53% | 167.77% | 154.26% |
| SG&A Expenses | 66.50% | 63.01% | 49.68% | 55.49% | 35.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -18.18% | -- | -- | -- | -- |
| Total Operating Expenses | 21.30% | 18.56% | 12.30% | 7.94% | 4.50% |
| Operating Income | -123.00% | 25.44% | 19.66% | 20.64% | 22.75% |
| Income Before Tax | -104.79% | 29.96% | 17.49% | 27.28% | 22.15% |
| Income Tax Expenses | 151.05% | 130.81% | 128.95% | -179.00% | -146.95% |
| Earnings from Continuing Operations | -110.72% | 28.61% | 15.97% | 28.56% | 26.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -110.72% | 28.61% | 15.97% | 28.56% | 26.67% |
| EBIT | -123.00% | 25.44% | 19.66% | 20.64% | 22.75% |
| EBITDA | -127.10% | 26.52% | 20.27% | 21.05% | 23.22% |
| EPS Basic | -98.01% | 32.82% | 22.06% | 33.96% | 30.58% |
| Normalized Basic EPS | -118.62% | 29.23% | 24.20% | 26.65% | 27.11% |
| EPS Diluted | -89.75% | 30.26% | 19.54% | 30.83% | 27.55% |
| Normalized Diluted EPS | -104.61% | 25.42% | 20.50% | 21.68% | 22.12% |
| Average Basic Shares Outstanding | 4.42% | 5.64% | 6.95% | 8.83% | 7.89% |
| Average Diluted Shares Outstanding | 0.68% | 9.44% | 10.82% | 12.80% | 11.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |